The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis

详细信息    查看全文

• 作者：Tianyi Gao^a ; ¹ ; Yanping Mei^a ; ¹ ; Huiling Sun^b ; Zhenlin Nie^a ; Xiangxiang Liu^b ; Shukui Wang^a ; ^b ; ^{shukwang@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：PTEN deletion ; Prostate cancer ; ERG rearrangements ; Prognostic value
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：83
• 期：Complete
• 页码：114-121
• 全文大小：1323 K

文摘

Phosphatase and tensin homolog (PTEN) deleted on chromosome 10, a tumor suppressor that negatively regulates the phosphoinositide-3-kinase(PI3 K) which has been implicated in a number of human malignancies including prostate cancer. However the prognostic value of PTEN deletion in prostate cancer patient’s diagnosis and the mechanism of PTEN deletion in prostate cancer development still remain unclear.

Method

A meta-analysis of 26 published studies including 8097 prostate cancer patients was performed.

Results

Compared to PTEN normal patients, PTEN deletion patients showed a higher aggressive Gleason score(OR: 1.284, 95%CI = 1.145–1.439) and pathological stage(OR: 1.628, 95%CI = 1.270–2.087) which generally had a higher risk in prostate replace(HR: 1.738, 95%CI = 1.264–2.390). Significant association between PTEN deletion and ERG rearrangements in prostate cancer development was also proved that compared to PTEN normal patients, patients with PTEN deletion showed a higher risk in ERG rearrangements(OR: 1.345, 95%CI = 1.102–1.788).

Conclusion

This study indicated that patients with PTEN deletion were associated with higher pathological stage or Gleason score and a higher risk in prostate cancer replace potentially represent a novel clinically relevant event to identify individuals at increased risk for the occurrence, progression and prognosis of prostate cancer. Prostate cancer patients with PTEN deletion usually had a higher risk in ERG rearrangements than other patients may be a potential new area for identifying poor prognosis patients and selecting patients for targeted therapies which required confirmation through adequately designed prospective studies.